Phathom Pharmaceuticals, Inc. 8-K

What Happened

• Phathom Pharmaceuticals announced on June 23, 2026 that it has completed enrollment in the Phase 2 pHalcon‑EoE‑201 study evaluating VOQUEZNA® (vonoprazan) tablets for eosinophilic esophagitis (EoE) in adults. The study enrolled 95 patients across 41 U.S. sites.
• pHalcon‑EoE‑201 is a two‑part, randomized, double‑blind, placebo‑controlled trial: Part 1 randomized 95 adults with endoscopically confirmed EoE and dysphagia evenly to VOQUEZNA 20 mg or placebo once daily for 12 weeks; Part 2 is a 12‑week extension where all participants receive VOQUEZNA 20 mg once daily. Topline results are anticipated in Q4 2026.

Key Details

• Enrollment: 95 adults at 41 U.S. sites.
• Dosing/design: VOQUEZNA 20 mg once daily vs placebo for 12 weeks (Part 1); 12‑week open extension with VOQUEZNA for all (Part 2).
• Next milestone: Topline data expected in the fourth quarter of 2026.
• Regulatory note: If results are positive, Phathom expects to discuss potential next steps with the FDA, including possible pediatric evaluation that could affect regulatory exclusivity.

Why It Matters

• For investors, this is a clinical‑stage development milestone that advances Phathom’s effort to expand VOQUEZNA into a new indication (EoE). Positive Phase 2 results could de‑risk the program and support further regulatory and commercial planning.
• The company highlights that a pediatric program could follow and potentially extend regulatory exclusivity, but also cautions these are forward‑looking plans subject to typical clinical, regulatory, and business risks (results may be negative or delayed, FDA discussions may not lead to pediatric studies or exclusivity, etc.). The Q4 2026 topline readout is the next clear catalyst.